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Abstract Excessive N-methyl-D-aspartate (NMDA)
receptor activation is widely accepted to mediate calcium-
dependent glutamate excitotoxicity. The uncompetitive,
voltage-dependent NMDA receptor antagonist memantine
has been successfully used clinically in the treatment of
neurodegenerative dementia and is internationally regis-
tered for the treatment of moderate to severe Alzheimer0s
disease. Glutamate release inhibitors (GRIs) may also be
promising for the therapy of some neurodegenerative dis-
eases. During the clinical use of GRIs, it could be questioned
whether there would still be a sufficient number of active
NMDA receptors to allow any additional effects of me-
mantine or similar NMDA receptor antagonists. To address
this question, we determined the fraction of NMDA recep-
tors contributing to postsynaptic events in the presence of
therapeutically relevant concentrations of the GRI riluzole
(1 lM) using an in vitro hippocampal slice preparation. We
measured the charge transfer of pharmacologically isolated
excitatory synaptic responses before and after the applica-
tion of the selective, competitive NMDA receptor antagonist
D-AP5 (100 lM). The fraction of activated NMDA recep-
tors under control conditions did not differ from those in the
presence of riluzole. It is therefore likely that NMDA
receptor antagonists would be able to exert additional ther-
apeutic effects in combination therapy with GRIs.
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Introduction
Glutamate is the major excitatory neurotransmitter in the
central nervous system (CNS). However, glutamatergic
dysfunction/excitotoxicity is also widely believed to be
involved in acute neurodegeneration (e.g., stroke and
trauma), chronic neurodegeneration (e.g., Parkinson’s dis-
ease, Alzheimer’s disease, Huntington’s disease, and
amyotrophic lateral sclerosis—ALS) as well as in the
symptomatology of numerous neurological and psychiatric
disorders (e.g., epilepsy, Parkinson’s disease, drug depen-
dence, depression, anxiety and chronic pain) (Beal 1995;
Danysz and Parsons 2002; Parsons et al. 1998; Plaitakis et al.
1996). Glutamate activates postsynaptic receptors, including
ionotropic 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)
proprionate (AMPA) and N-methyl-D-aspartate (NMDA)
receptors allowing the influx of Ca2+ ions—especially
though the later and, in some cases, the former if edited
GluR2 subunits are absent (Burnashev et al. 1992). Although
physiological elevations in intracellular Ca2+ are salient to
normal cell functioning, the excessive or persistent influx of
Ca2+ together with any Ca2+ release from intracellular
compartments can overwhelm Ca2+-regulatory mechanisms
and lead to cell death/excitotoxicity (Arundine and Tymi-
anski 2003; Danysz and Parsons 2002; Krieger et al. 1996;
Muir et al. 1995; Wenk et al. 2006) and additionally to
symptomatological disturbances, especially those involving
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pathological long-term plastic changes (e.g., chronic pain,
drug abuse, epilepsy) (Arundine and Tymianski 2003; Par-
sons et al. 1998, 2007; Rogawski 2006).
Data from animal models clearly suggest that modulation
of glutamate function may be highly beneficial in the
treatment of various neurodegenerative/neurological disor-
ders in humans. Reduced glutamate tone may be achieved
by different pharmacological interventions, two of which
are especially important for the present study: first, antag-
onising/modulating post-synaptic receptors such as NMDA
receptors and second, reducing glutamate release/or
increasing uptake at pre-synaptic glutamatergic terminals.
Memantine is a clinically very well tolerated uncom-
petitive NMDA receptor antagonist (Chen et al. 1992;
Parsons et al. 1993, 2007) and its protective effects have
been shown in various models of acute and chronic neu-
rodegeneration (Chen and Lipton 1997; Chen et al. 1992;
Miguel-Hidalgo et al. 2002; Wenk et al. 1997; for review
see Parsons et al. 1999, 2007; Wenk et al. 2006).
The application of so-called glutamate release inhibitors
(GRIs) e.g., riluzole, lamotrigine, phosphophenytoin,
gabapentin, pregabalin and lubeluzole may be another
promising approach for the therapy of neurodegenerative
diseases due to their mode of action: blockade of overac-
tive glutamate transmission before it becomes neurotoxic
or impedes neuronal discharges during seizures (Parsons
et al. 1998). Lamotrigine, for example is an anti-epileptic
agent, whereas lubeluzole has been reported to be effective
in patients with acute ischaemic stroke (Diener 1998).
Riluzole moderately slows disease progression in ALS
patients (Bensimon et al. 1994; Lacomblez et al. 1996) and
is currently the only approved drug for the treatment of
ALS (Gordon 2005; Miller et al. 2007; Parsons and Danysz
2002; Traynor et al. 2006; Van Damme et al. 2005).
The effects of riluzole on the glutamatergic system has
been claimed to have both a pre- and postsynaptic locus,
although the evidence for the former is more conclusive
(MacIver et al. 1996) for reviews see (Doble 1996; Gordon
2005; Miller et al. 2007; Parsons and Danysz 2002; Tray-
nor et al. 2006; Van Damme et al. 2005). Both, in vitro and
in vivo experiments have provided data indicating that
riluzole has a higher potency to decrease NMDA-evoked
responses than those mediated by non-NMDA receptors
see (Mantz 1996). It is widely accepted that the effects of
rilzuole in ALS are, at best, moderate, and that a combi-
nation of drugs with different mechanisms of action might
be a more promising therapeutic approach (Goodall and
Morrison 2006; McGeer and McGeer 2005; Van Den
Bosch et al. 2006; Weiss et al. 2004). However, it remains
an open question whether there would still be a sufficient
number of active NMDA receptors available during riluz-
ole therapy to allow any additional effect of NMDA
receptor antagonists if such compounds were administered
in combination with riluzole in order to increase the
treatment effect size in this very severe disorder.
When taken as an example indication, clinical mono-
therapy trials in ALS are probably not ethically justifiable
due to the severity of this disease. Moreover, other gluta-
matergic combination therapies show promise in various
animal models and can increase therapeutic effects whilst
even reducing side effects—the best preclinical example
might seem to be the combination of AMPA and NMDA
receptor antagonists in epilepsy (Lo¨scher et al. 1993). In the
present study we recorded evoked synaptic events in the CA1
region of murine hippocampal brain slices to determine the
magnitude of the NMDA receptor contribution after the
application of clinically relevant concentrations of riluzole.
Whilst the spinal cord is probably the main target tissue
for the therapeutic effects of riluzole in ALS, we chose to
use hippocampal slices as a model tissue relevant for the
combined use of GRIs and NMDA receptor antagonists in
numerous other indications where therapeutic efficacy of
either treatment has been implicated by preclinical studies.
NMDA receptors are highly expressed and play a pivotal
role in glutamatergic transmission in this structure.
Material and methods
Brain slice preparation
Sagital hippocampal slices (300 lm thick) were obtained
from young adult (6–8 weeks) male mice that were
anaesthetized with ether before decapitation. The experi-
mental protocols were approved by the Ethical Committee
on Animal Care and Use of the Government of Bavaria,
Germany. The brain was rapidly removed, and slices were
prepared in ice-cold Ringer solution using a vibroslicer
(Microm, Walldorf, Germany). To minimize epileptiform
activity the CA3 region was removed. All slices were
placed in a holding chamber for at least 60 min and were
then transferred to a submerged superfusing chamber for
extracellular or whole-cell recordings. The flow rate of the
solution through the chamber was 1.5 ml/min. The com-
position of the extracellular solution was 124 mM NaCl,
3 mM KCl, 26 mM NaHCO3, 2 mM CaCl2, 1 mM
MgSO4, 10 mM D-glucose, and 1.25 mM NaH2PO4, bub-
bled with a 95% O2–5% CO2 mixture, and had a final pH of
7.3. All experiments were performed at room temperature.
Electrophysiological recording
Extracellular recordings of field excitatory postsynaptic
potentials (fEPSPs) were obtained from the dendritic
region of the CA1 region of the hippocampus using glass
micropipettes (1–2 MX) filled with superfusion solution.
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Whole-cell recordings of excitatory postsynaptic currents
(EPSCs) were obtained from somata of pyramidal neurons
of the CA1 region by means of the blind patch clamp
technique (Blanton et al. 1989). The pipettes for whole-cell
recording were filled with 130 mM CH4SO3, 130 mM
CsOH, 0.05 mM EGTA, 5 mM HEPES, 1 mM MgCl2,
1 mM NaCl, and 5 mM QX314 and displayed resistances
between 4.5 and 5 MX. To isolate glutamatergic dual
component EPSCs, slices were perfused with picrotoxin
(50 lM) and CGP 35348 (200 lM) to block c-aminobutyric
acid type A (GABAA) and type B (GABAB) receptors,
respectively. Voltage-activated sodium and potassium
channels were blocked by QX-314 and CsOH, applied
intracellularly via the recording pipette. Currents were
recorded with a switched voltage clamp amplifier (SEC-
10L; NPI Electronics, Tamm, Germany) with switching
frequencies of 80 kHz (25% duty cycle). Series resistance
was monitored and continuously compensated in bridge
mode. Neuronal input resistance was measured by injecting
hyperpolarizing current pulses (300 ms, -10 mV).
EPSCs and fEPSPs were evoked by stimuli (0.033 Hz,
4–5 V, 20 ls), delivered via a bipolar tungsten electrodes
insulated to the tip (5 lm tip diameter) and positioned in
the Schaffer collateral–commissural pathway. To deter-
mine the magnitude of the NMDA receptor contribution to
responses in the presence of riluzole (1 lM), we measured
the charge/voltage transfer of the pharmacologically iso-
lated dual component fEPSPs and EPSCs before and after
the application of the competive NMDA receptor antago-
nist D-(-)-2-amino-5-phosphono-pentanoic acid (D-AP5;
100 lM)—this compound was chosen for these experi-
ments because it is highly selective for NMDA receptors
and shows rapid penetration into in vitro tissue slices and
can also be rapidly washed out.
All experiments were performed at room temperature at
a holding potential of -60 mV. The recordings were fil-
tered (3 kHz) and the digitized (9 kHz) data were stored
using a Power Macintosh G3 computer by a data acquisi-
tion and evaluation program (Pulse v. 8.5; Heka electronic
GmbH, Lambrecht, Germany).
Statistical analysis was carried out using the Student’s
paired t test to compare the values of 10 min of a stable
baseline (control), and after application of D-AP5.
P \ 0.05 was considered as a significant difference. Data
are presented as mean ± SEM.
Results
Effects of riluzole on synaptic transmission
In previous studies it has been shown that riluzole
(5–20 lM) depresses glutamatergic synaptic responses in
hippocampal slices and autaptic microculture neurons
(MacIver et al. 1996; Martin et al. 1993; Prakriya and
Mennerick 2000) by pre-synaptic mechanisms such as the
inhibition of voltage-activated sodium and/or N- and P/Q-
type calcium channels (Huang et al. 1997; Song et al. 1997;
Stefani et al. 1997). Here, the amplitude and area under the
curve (charge transfer) of glutamatergic dual component
EPSCs, mediated by AMPA- and NMDA-receptors, were
concentration-dependently reduced by the application of
1 lM and 10 lM riluzole (EPSC amplitude (1 lM)
88.5 ± 6.1%, (10 lM) 44.5 ± 13.9%; EPSC charge
transfer (1 lM) 61.8 ± 7.3%, (10 lM) 49.2 ± 13.3%;
n = 7; Fig. 1; P \ 0.05). Albeit with no clear concentra-
tion–response relationship, riluzole also affected the decay
of the EPSC and reduced the time constant s to 74.9 ± 8.5
and 83.6 ± 8.1% for 1 and 10 lM, respectively (Fig. 1).
Both concentrations were significantly different to control
(P \ 0.05) but not to each other (P [ 0.05).
Determination of the fraction of functional NMDA
receptors after the application of riluzole (1 lM)
For the measurement of AMPA and NMDA receptor
components mediating a single-evoked response, we
Fig. 1 Riluzole, concentration-dependently reduced dual component
EPSC charge and amplitude. a, b The application of 1 and 10 lM
riluzole reduced EPSC amplitude. Representative traces are shown,
original (left), normalized (right). Each traces in each figure recorded
from one neuron, respectively. c Averaged data showing the effect of
riluzole on EPSC amplitude, charge and time constant s
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analysed the EPSC with different parameters and at dif-
ferent times following the stimulus (see Clark and
Collingridge 1995; Fig. 2a). This is illustrated by the cur-
rent–voltage (I–V) relationship (Fig. 2a); the initial slope of
the response (10–60% before the peak) is believed to be
mainly mediated by AMPA receptors, whereas the ampli-
tude of the later response (measured at 80 ms after the
stimulus) displayed the expected NMDA receptor I–V
function. As a further parameter, we assessed the charge
transfer of the EPSC. After the EPSC responses were sta-
ble, either under control conditions or in the presence of
riluzole (1 lM), D-AP5 (100 lM) was applied to ensure
complete block of NMDA receptors. Under control con-
ditions, D-AP5 reduced the initial slope and the response
amplitude at 80 ms after the initial stimulation to
75.9 ± 12.7 and 46.6 ± 10.3%, respectively (n = 7; Fig.
2b, c, both P \ 0.05). During the application of riluzole,
the D-AP5-induced effect on the ‘‘AMPA receptor’’ and
the ‘‘NMDA receptor’’-mediated components was similar
and showed no statistically significant difference to
experiments in the absence of riluzole. The initial slope
was decreased to 77.8 ± 13.2% and the amplitude of the
response at 80 ms was 37.2 ± 6.6% (n = 7; Fig. 2b, c,
both P \ 0.05 compared to control but P [ 0.05 compared
to riluzole). These results demonstrate that the proportion
of active NMDA receptors was not affected by the pres-
ence of riluzole. However, the application of D-AP5 did
indeed affect the amplitude of the dual component EPSC as
well as the initial slope indicating that these parameters
were clearly not exclusively mediated by AMPA receptor
activation under our experimental conditions. Therefore,
measurement of the charge transfer during the EPSC
seemed to be a more precise parameter for the assessment
of the magnitude of the contribution of NMDA receptor
activation to this glutamateric synaptic signal. The charge
transfer was calculated as the area under the curve of the
EPSC. The decrease of the charge transfer of the EPSC
with D-APV under control conditions did not differ from
that in the presence of riluzole (control: 49.3 ± 11.7%;
riluzole: 53.9 ± 5.1%; p [ 0.05, n = 7; Fig. 2c). In other
words, riluzole did not affect the fraction of functional
NMDA receptors contributing to the EPSC, neither when
EPSC amplitude at 80 ms was assesssed (control:
54.5 ± 10.7%, riluzole: 63.4 ± 6.3%, P [ 0.05) nor
when EPSC charge transfer was used as a quantifier
(control: 50.5 ± 11.3%, riluzole: 46.2 ± 4.4%; P [ 0.05;
Fig. 2d).
In the next set of experiments we investigated the effects
of riluzole on NMDA receptor contribution to synaptic
potentials under somewhat more physiological conditions
by performing extracellular field potential recordings
without clamping the neurons at a specific membrane
potential. As a measurement parameter we again calculated
the fEPSP ‘‘voltage’’ transfer i.e. the area under the fEPSP
curve. Riluzole (1 lM) per se decreased fEPSPs to
70.0 ± 5.9% (n = 8; Fig. 3a). When D-AP5 was applied,
the ‘‘additional’’ change in the fEPSP evoked in control
slices and those already exposed to riluzole showed no
significant difference (fEPSP control: 73.5 ± 4.0%; riluz-
ole: 81.2 ± 5.9%; P [ 0.05, n = 10; Fig. 3b). The fraction
of activated NMDA receptors under control conditions
therefore did not differ significantly from those in the
presence of riluzole (fEPSP control: 30.0 ± 6.3%; riluzole:
26.5 ± 9.5%; P [ 0.05, n = 10; Fig. 3c).
Discussion
Memantine is approved for the therapy of moderate to
severe Alzheimer’s disease, but preclinical data indicate
high therapeutic potential in many other diseases related to
neurodegeneration (Parsons et al. 1999; Rammes et al.
2008; Wenk et al. 2006). Riluzole is the only medication
approved for the treatment of ALS and has been registered
as a neuroprotective agent in several countries. On the
other hand, riluzole has also been considered for thera-
peutic use in dementia and epilepsy (Doble 1996; Gordon
2005; Miller et al. 2007; Parsons and Danysz 2002; Van
Damme et al. 2005). Lamotrigine, gabapentin and the
related pregabalin are registered for therapy in epilepsy
(Rogawski 2006; Zipp et al. 1993) and phosphophenytoin
is in phase II trials for stroke and ischaemia. In other
words, in some CNS disorders, treatment with NMDA
receptor antagonists might have to be in combination with
other anti-glutamatergic agents—the best example of
which would seem to be with riluzole in ALS (Goodall and
Morrison 2006; McGeer and McGeer 2005; Van Den
Bosch et al. 2006; Weiss et al. 2004).
It is therefore important to consider whether there would
still be a sufficient number of active NMDA receptors to
allow for any additional effects of an NMDA receptor
antagonist with such combinations. Furthermore, in vitro
and in vivo experiments have shown that riluzole has a
higher potency to decrease the NMDA-evoked responses
than that of non-NMDA receptors (see Mantz 1996). Under
such assumptions it might be concievable that the contri-
bution of NMDA receptors underlying the dual component
EPSC is significantly reduced in the presence of a GRI like
riluzole.
In the present study, we demonstrated that the fraction
of activated NMDA receptors during synaptic transmission
to CA1 hippocampal neurons remained constant in the
presence of the glutamate release inhibitor riluzole, which
would indicate that additional effects would indeed be
possible with an NMDA receptor antagonist during com-
bination therapy.
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Despite extensive studies, the precise mechanism of
action of riluzole remains elusive. However, effects on
voltage-activated Na+ channels (Benoit and Escande 1991),
background K+-channels (Duprat et al. 2000), GABA
uptake ((Mantz et al. 1994)) and voltage-activated Ca2+-
channels (Huang et al. 1997) have been suggested. Non-
theless, riluzole clearly decreases the synaptic release of
glutamate (Cheramy et al. 1992; Martin et al. 1993;
Umemiya and Berger 1995) and this effect is probably
secondary to inhibition of voltage-activated Na+ channels
(Doble 1996; MacIver et al. 1996; Yokoo et al. 1998).
Other recent findings indicate that riluzole not only
decreases glutamate release, but also enhances glutamate
uptake (Azbill et al. 2000; Frizzo et al. 2004). Interestingly,
Fig. 2 The fraction of activated
NMDA receptors under control
conditions did not differ from
those in the presence of riluzole.
a, left Voltage-dependence of
dual-component EPSCs. The
symbols on the EPSC indicate
where the AMPA and NMDA
receptor-mediated synaptic
components were measured; the
slope between 10 and 60% of
peak amplitude (open circles)
and the amplitude at 80 ms
following the stimulus (closed
circles), respectively. a, right
The corresponding current-
voltage plot for the same cell. b
Representative traces, original
(left), normalized (right),
showing the effect of D-AP5
(100 lM) on the EPSC
responses with (below) and
without (top) riluzole. c
Average of all experiments: D-
AP5 reduced the initial slope,
the amplitude at a latency of
80 ms (left) and the charge of
the EPSC (right). In the
presence of riluzole, the D-AP5-
induced effect on the AMPA
receptor and the NMDA
receptor component was similar
and showed no statistically
significant difference. d The
proportion of active NMDA
receptors was not attenuated in
the presence of riluzole
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this effect was reported for concentrations reached under
standard clinical conditions (Frizzo et al. 2004), similar to
those used in the present study.
Whatever, the MoA on glutamate release/uptake, such
effects agree well with the results of the present study in
which riluzole concentration-dependently reduced isolated
dual-component EPSCs in CA1 neurons.
At synapses of CA1 pyramidal neurons, where gluta-
mate is rapidly cleared from the synaptic cleft, the decay
time of synaptic currents is determined primarily by the
deactivation time constants of AMPA and NMDA recep-
tors (Silver et al. 1996). This is believed to be the main
factor shaping the decay of EPSCs at cortical synapses
(Hestrin 1992). Although measurements at a holding
potential of -60 mV normally provide the best separation
of AMPA and NMDA receptor-mediated components of a
dual component EPSCs (Clark and Collingridge 1995), in
the present experiments, the application of D-AP5 also
affected both the amplitude of the dual component EPSC
and also the initial slope indicating that these parameters
were not exclusively associated with AMPA receptor
activation. As such, the measurement of changes in the
charge transfer of the EPSC in the presence of D-APV was
deemed to be the most precise parameter for the assessment
of the magnitude of NMDA receptor contribution to the
synaptic signals recorded in the present experiments. These
results were confirmed under more physiological condi-
tions, when recording extracellulary from a population of
neurons without clamping the membrane potential.
However, in the present experiments, riluzole affected
both EPSC amplitude and charge transfer but had little
selective effect on deactivation time. Moreover, measuring
either the EPSC amplitude at a post-stimulus time of 80 ms
or the charge transfer of pharmacologically isolated dual
component EPSCs before and after the application of the
NMDA receptor antagonist D-AP5 demonstrated that the
fraction of activated NMDA receptors under control con-
ditions did not differ from those in the presence of riluzole.
There is compelling evidence that abnormal activation
of NMDA receptors and NMDA receptor-mediated ex-
citotoxicity is involved in many CNS disorders (Rothstein
1995; Shaw and Ince 1997; Wenk et al. 2006). Conse-
quently, the NMDA receptor antagonist memantine has
been shown to have therapeutic potential in preclinical
models of various neurodegenerative diseases and shows
clear clinical symptomatic improvement in Alzheimer0s
disease (Danysz and Parsons 2003; Parsons et al. 1999,
2007). Another promising approach to ameliorate gluta-
matergic dysfunction might be the use of memantine in
combination with selective inhibitors of glutamate release
to gain additional therapeutic benefits and further reduce
possible side effects. GRIs show therapeutic limitations;
however, e.g., although riluzole has been shown to prolong
the survival of motor neuron in ALS, its effects on the
progression of disease are not consistent (Bensimon et al.
1994; Lacomblez et al. 1996). The combination of riluzole
with NMDA receptor antagonists may therefore be more
clinically useful in ALS patients to prolong neural survival
(Goodall and Morrison 2006; McGeer and McGeer 2005;
Van Den Bosch et al. 2006; Weiss et al. 2004). In fact,
memantine has been shown to have therapeutic effects in a
mouse model of ALS (Wang and Zhang, 2005). Further-
more, memantine also shows antiepileptic activity (Parsons
et al. 1999) which might be useful in combination with
gabapentin or pregabalin, two further modulators of syn-
aptic release, particularly of glutamate, through direct
actions on release machinery (Rogawski 2006).
The results of the present study clearly demonstrates that
NMDA receptors may be a valid pharmacological target
during treatment with glutamate release inhibitors.
Fig. 3 Extracellular recordings, without clamping the neurons,
demonstrating similar results for riluzole on the contribution of
NMDA receptors to the synaptic signal. As a measurement parameter
we calculated the fEPSP charge. a Riluzole (1 lM) per se decreased
fEPSP charge. b When D-AP5 was applied, the charge of the fEPSP
evoked in control slices and those already exposed to riluzole (1 lM)
showed no significant difference. c The fraction of activated NMDA
receptors under control conditions did not differ from those in the
presence of riluzole (1 lM)
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